Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 4/20 | 0.68 |
| ▸ | HTR2B | P41595 | 3/20 | 0.68 |
| ▸ | HTR1D | P28221 | 2/20 | 0.68 |
| ▸ | HTR1B | P28222 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | MPO | P05164 | 5/20 | 0.64 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR1E | P28566 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21292743 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL19412024 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| Hydrochloric Acid SCHEMBL20242634 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| Hydrochloric Acid SCHEMBL31143423 | 0.98 | HTR2A (0.97) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL24178315 | 0.89 | HTR2A (0.80) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL28069265 | 0.89 | HTR2A (0.80) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL29528195 | 0.89 | HTR2A (0.80) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL274680 | 0.89 | HTR2A (0.80) | HTR2AHTR2CHTR1AHTR2BHTR1D | |
| SCHEMBL22923386 | 0.87 | HTR2A (0.77) | HTR2AHTR2CHTR1AMPOGPR84 | |
| SCHEMBL25396760 | 0.85 | HTR2A (1.00) | HTR2AHTR2CHTR1AMPOGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| US-20010008641-A1 | NUTRITIONALLY ACTIVE COMPOSITION FOR BODYBUILDING | ADAMS FOODS, LTD. | 2001-07-19 | — | — | US | claimed |
| WO-2000003679-A2 | NUTRITIONALLY ACTIVE COMPOSITION FOR HARDENING FINGERNAILS | ADAMS FOOD LTD. (US) | 2000-01-27 | — | — | WO | claimed |
| WO-1999061038-A1 | COMPOSITION HAVING THERAPEUTIC AND/OR NUTRITIONALLY ACTIVE SUBSTITUENT | ADAMS FOOD LTD. (US) | 1999-12-02 | — | — | WO | claimed |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | CAAMTECH, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | KULEON LLC (US) | 2026-04-02 | — | — | US | disclosed |
| EP-3760623-B1 | TETRAHYDRO-PYRIDO[3,4-B]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | HOFFMANN LA ROCHE (CH) | 2026-03-18 | — | — | EP | disclosed |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-10 | — | — | US | disclosed |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | Park City Bio, LLC (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | Park City Bio, LLC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-7060698-B2 | Benzoxazepinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1631296-A1 | 2,3,4,5-TETRAHYDROBENZO[F][1,4]OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004100958-A1 | 2, 3, 4, 5-TETRAHYDROBENZO[F][1, 4]OXAZEPINE-5-CARBOXYLIC ACID AMIDE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER’S DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-25 | — | — | WO | disclosed |
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | HOFFMANN-LA ROCHE INC. | 2004-11-25 | — | — | US | disclosed |
| US-20010008641-A1 | NUTRITIONALLY ACTIVE COMPOSITION FOR BODYBUILDING | ADAMS FOODS, LTD. | 2001-07-19 | — | — | US | disclosed |
| WO-2000003679-A2 | NUTRITIONALLY ACTIVE COMPOSITION FOR HARDENING FINGERNAILS | ADAMS FOOD LTD. (US) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999061038-A1 | COMPOSITION HAVING THERAPEUTIC AND/OR NUTRITIONALLY ACTIVE SUBSTITUENT | ADAMS FOOD LTD. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376436-A1 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | HTR1A, HTR4, HTR5A | HTR2A 8/4885HTR2C 7/4885HTR1A 1/4885 |
| US-20260092034-A1 | 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME | HTR2C, HTR7, HTR6 | HTR2A 6/4885HTR2C 1/4885HTR1A 5/4885 |
| US-20040235819-A1 | 5-alkylaminocarbonyl-substituted, e.g., 4-(1-benzyl-piperidin-4-yl)-2-isopropyl-3-oxo-2,3,4,5-tetrahydro-benzo[f][1,4]oxazepine-5-carboxylic acid tert-butylamide; gamma -secretase inhibitors for the treatment of Alzheimer's disease. | BACE1, BACE2, PSEN1 | HTR2A 771/4885HTR2C 1012/4885HTR1A 767/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | HTR2A 14/4885HTR2C 42/4885HTR1A 9/4885 |
| US-20260108493-A1 | COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND | ADRA2C, ADRB3, ADRA2B | HTR2A 19/4885HTR2C 12/4885HTR1A 22/4885 |
| US-12570602-B2 | Selective serotonin receptor modulators and methods of making and using the same | HTR1D, HTR1A, HTR4 | HTR2A 14/4885HTR2C 6/4885HTR1A 2/4885 |
| US-12564560-B1 | Selective serotonin receptor modulators and methods of making and using the same | HTR5A, HTR1A, HTR1D | HTR2A 16/4885HTR2C 7/4885HTR1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.